GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » Beta

Entheon Biomedical (XCNQ:ENBI) Beta : 1.57 (As of Apr. 30, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-04-30), Entheon Biomedical's Beta is 1.57.


Entheon Biomedical Beta Historical Data

The historical data trend for Entheon Biomedical's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical Beta Chart

Entheon Biomedical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Nov21 Nov22 Nov23
Beta
Get a 7-Day Free Trial - - 2.94 1.84 0.67

Entheon Biomedical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.84 2.79 1.87 1.74 0.67

Competitive Comparison of Entheon Biomedical's Beta

For the Biotechnology subindustry, Entheon Biomedical's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entheon Biomedical's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entheon Biomedical's Beta distribution charts can be found below:

* The bar in red indicates where Entheon Biomedical's Beta falls into.



Entheon Biomedical Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Entheon Biomedical  (XCNQ:ENBI) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Entheon Biomedical Beta Related Terms

Thank you for viewing the detailed overview of Entheon Biomedical's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Entheon Biomedical (XCNQ:ENBI) Business Description

Traded in Other Exchanges
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.

Entheon Biomedical (XCNQ:ENBI) Headlines

No Headlines